Literature DB >> 8520756

Decline in FEV1 among patients with severe hereditary alpha 1-antitrypsin deficiency type PiZ.

N Seersholm1, A Kok-Jensen, A Dirksen.   

Abstract

Severe alpha 1-antitrypsin (alpha 1-AT) deficiency is characterized by a decrease in serum alpha 1-AT to values < 20% of normal. Severe airflow obstruction, most commonly due to pulmonary emphysema secondary to the destruction of pulmonary elastic tissue, may develop at an early age in persons with alpha 1-AT deficiency. The purpose of this study was to estimate the annual decline in FEV1 (delta FEV1) in alpha 1-AT-deficient patients, to compare delta FEV1 in a referral population (index cases) with subjects found through family studies (nonindex cases), and to evaluate the role of smoking cessation on delta FEV1. One hundred and sixty-one subjects from the Danish alpha 1-AT-deficiency study who were older than 25 yr and who had a recorded smoking history and at least two spirometric examinations 1 yr apart were studied. The delta FEV1 for each individual was determined by regression analysis of FEV1 on follow-up time. The overall mean delta FEV1 was 81 ml/yr. There was no significant difference in delta FEV1 between 113 index cases and 48 nonindex cases even after controlling for age, initial FEV1, sex, and lifetime tobacco consumption. One hundred of the subjects were ex-smokers, 18 had never smoked, and 43 were current smokers. The mean delta FEV1 among the current smokers was 132 ml/yr, versus 52 ml/yr among the ex-smokers (p < 0.001). For the never-smokers, the mean delta FEV1 was 86 ml/yr.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8520756     DOI: 10.1164/ajrccm.152.6.8520756

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  19 in total

1.  Secreted modular calcium-binding protein 2 haplotypes are associated with pulmonary function.

Authors:  Jemma B Wilk; Alan Herbert; Christina M Shoemaker; Daniel J Gottlieb; Samer Karamohamed
Journal:  Am J Respir Crit Care Med       Date:  2007-01-04       Impact factor: 21.405

Review 2.  Late onset genetic disease: where ignorance is bliss, is it folly to inform relatives?

Authors:  J T Wilcke
Journal:  BMJ       Date:  1998-09-12

3.  Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics.

Authors:  D Soy; C de la Roza; B Lara; C Esquinas; A Torres; M Miravitlles
Journal:  Thorax       Date:  2006-08-23       Impact factor: 9.139

4.  Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency.

Authors:  Dawn L Demeo; Robert A Sandhaus; Alan F Barker; Mark L Brantly; Edward Eden; N Gerard McElvaney; Stephen Rennard; Esteban Burchard; James M Stocks; James K Stoller; Charlie Strange; Gerard M Turino; Edward J Campbell; Edwin K Silverman
Journal:  Thorax       Date:  2007-03-27       Impact factor: 9.139

Review 5.  Chronic obstructive pulmonary disease. 1: Susceptibility factors for COPD the genotype-environment interaction.

Authors:  A J Sandford; E K Silverman
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

Review 6.  Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history.

Authors:  M Needham; R A Stockley
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

Review 7.  Why is Disease Penetration so Variable in Alpha-1 Antitrypsin Deficiency? The Contribution of Environmental Factors.

Authors:  Madhu Rangaraju; Alice M Turner
Journal:  Chronic Obstr Pulm Dis       Date:  2020-07

8.  Clinical features and prognosis of life time non-smokers with severe alpha 1-antitrypsin deficiency.

Authors:  N Seersholm; A Kok-Jensen
Journal:  Thorax       Date:  1998-04       Impact factor: 9.139

9.  Level and course of FEV1 in relation to polymorphisms in NFE2L2 and KEAP1 in the general population.

Authors:  Mateusz Siedlinski; Dirkje S Postma; Jolanda M A Boer; Gerrit van der Steege; Jan P Schouten; Henriette A Smit; H Marike Boezen
Journal:  Respir Res       Date:  2009-08-11

10.  Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank.

Authors:  Adriano R Tonelli; Farshid Rouhani; Ning Li; Pam Schreck; Mark L Brantly
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.